Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115607 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Rosa Di Micco und 30 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: dimicco.rosa@hsr.it. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymph Nodes, Neoadjuvant Therapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Merit Medical Systems.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Assessing the axillary response to neoadjuvant chemotherapy (NACT) in patients with initially node-positive breast cancer is crucial to determine the most appropriate surgical approach. While axillary ultrasound (AUS) is a well-established tool in the upfront surgery setting, its performance after NACT is still questioned. Here, we assess the reliability of AUS in predicting the pathological axillary status after NACT using data from the large prospective multicenter AXSANA trial. METHODS: Between June 1, 2020, and May 31, 2024, 5.559 patients were enrolled in the AXSANA trial. For this analysis, patients with clinically node-positive breast cancer who underwent AUS after NACT were eligible. AUS`s sensitivity, specificity, positive (PPV) and negative predictive value (NPV) were analyzed using surgical staging as reference. FINDINGS: 3840 patients were eligible for this analysis. Of these, 3428(89.3 %) patients underwent preoperative AUS after NACT, classified as unclear in 168(4.9 %), positive in 1060(30.9 %) and negative in 2200 (64.2 %). An axillary pathological complete response (pCR) was achieved in 1793(55.0 %). Nodal metastases were detected in 786 of 2200 patients (35.7 %) with an negative AUS, while 379(35.8 %) of 1060 patients with a positive AUS achieved an axillary pCR. AUS sensitivity was 46.4 %(95 % CI 43.8 %-49.0 %), specificity 78.9 %(76.9 %-80.7 %), PPV 64.2 %(61.3 %-67.1 %), and NPV 64.3 %(62.2 %-66.3 %). PPV was highest for HR+ /HER2- tumors (81.9 %, 78.9 %-85.2 %), NPV for HR-/HER2 + tumors (88.3 %, 84.2 %-91.7 %). Triple negative and HER2 + subtypes were significantly less frequently associated with false-negative AUS results than an HR+ /HER2- cancer. INTERPRETATION: AUS alone does not reliably predict pathological nodal status. Axillary lymph node dissection based on positive AUS findings after NACT results in surgical overtreatment. Surgical axillary staging after NACT remains essential for the accurate assessment of axillary lymph node status in patients with initially node-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Surgery Unit, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: dimicco.rosa@hsr.it.
- Department of Gynecology and Obstetrics, University Hospital Rostock, Rostock, Germany.
- Department of Obstetrics and Gynecology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Surgery, Breast Center, Capio St. Göran's Hospital, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Gynecology, Operative and Conservative Senology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Department of Gynecology and Obstetrics, University Hospital Aachen, Aachen, Germany.
Förderung
- Merit Medical Systems
Zitieren
APA
Di Micco, R., Hartmann, S., Banys-Paluchowski, M., de Boniface, J., Schmidt, E., Ditsch, N., Stickeler, E., Schroth, J., Karadeniz Cakmak, G., Hahn, M., Thill, M., Lux, M. P., Kolberg, H. C., Rubio, I. T., Gasparri, M. L., Kontos, M., Bonci, E. A., Niinikoski, L., Murawa, D., …, & AXSANA Study Group (2025). Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115607
Vancouver
Di Micco R, Hartmann S, Banys-Paluchowski M, de Boniface J, Schmidt E, Ditsch N, et al. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115607
BibTeX
@article{DiMicco2025,
author = {Di Micco, Rosa and Hartmann, Steffi and Banys-Paluchowski, Maggie and de Boniface, Jana and Schmidt, Esther and Ditsch, Nina and Stickeler, Elmar and Schroth, Jennifer and Karadeniz Cakmak, Guldeniz and Hahn, Markus and Thill, Marc and Lux, Michael Patrick and Kolberg, Hans-Christian and Rubio, Isabel T and Gasparri, Maria Luisa and Kontos, Michalis and Bonci, Eduard-Alexandru and Niinikoski, Laura and Murawa, Dawid and Pinto, David and Peintinger, Florentia and Schlichting, Ellen and Nina, Helidon and Valiyeva Qanimat, Hagigat and Vanhoeij, Marian and Rebaza, Lia and Kadayaprath, Geeta and Porpiglia, Mauro and Gentilini, Oreste Davide and Kühn, Thorsten and AXSANA Study Group, AXSANA Study Group},
title = {Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115607}
}
EUVIMED